Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 15.3% | 13.8% | 12.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 53.8% | 54.7% | 55.3% | 46% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 13.3% | 12.9% | 9.6% | -15.7% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 10.2% | 11.4% | 6.2% | -7.3% |
| EPS | 0.25 | 0.24 | 0.12 | -0.12 |
| % Growth | 4.2% | 100% | 200% | – |
| EPS Diluted | 0.23 | 0.23 | 0.11 | -0.12 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 15.2% | 13.1% | 9.9% | -13.5% |